{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T12:05:55Z","timestamp":1774008355922,"version":"3.50.1"},"reference-count":74,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T00:00:00Z","timestamp":1618358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Macrolides (e.g., erythromycin, fidaxomicin, clarithromycin, and azithromycin) are a class of bacteriostatic antibiotics commonly employed in medicine against various gram-positive and atypical bacterial species mostly related to respiratory tract infections, besides they possess anti-inflammatory and immunomodulatory effects. Coronavirus Disease 2019 (COVID-19) is an infectious disease caused by the severe acute respiratory syndrome of coronavirus 2 (SARS-CoV-2). It was first detected in Wuhan, Hubei, China, in December 2019 and resulted in a continuing pandemic. Macrolides have been extensively researched as broad adjunctive therapy for COVID-19 due to its immunostimulant abilities. Among such class of drugs, azithromycin is described as azalide and is well-known for its ability to decrease the production of pro-inflammatory cytokines, including matrix metalloproteinases, tumor necrosis factor-alpha, interleukin (IL)-6, and IL-8. In fact, a report recently published highlighted the effectiveness of combining azithromycin and hydroxychloroquine for COVID-19 treatment. Indeed, it has been underlined that azithromycin quickly prevents SARS-CoV-2 infection by raising the levels of both interferons and interferon-stimulated proteins at the same time which reduces the virus replication and release. In this sense, the current review aims to evaluate the applications of macrolides for the treatment of COVID-19.<\/jats:p>","DOI":"10.3389\/fmed.2021.642313","type":"journal-article","created":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T08:16:36Z","timestamp":1618388196000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Management of SARS-CoV-2 Infection: Key Focus in Macrolides Efficacy for COVID-19"],"prefix":"10.3389","volume":"8","author":[{"given":"Gaber El-Saber","family":"Batiha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marwa A.","family":"Zayed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aya A.","family":"Awad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hazem M.","family":"Shaheen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suleiman","family":"Mustapha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oscar","family":"Herrera-Calderon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge Pamplona","family":"Pagnossa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdelazeem M.","family":"Algammal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Zahoor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Achyut","family":"Adhikari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ishan","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara T.","family":"Elazab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kannan R. R.","family":"Rengasamy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nat\u00e1lia","family":"Cruz-Martins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helal F.","family":"Hetta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,4,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1007\/s12015-020-09976-7","article-title":"CD147 as a target for COVID-19 treatment: suggested effects of azithromycin and stem cell engagement","volume":"16","author":"Ulrich","year":"2020","journal-title":"Stem Cell Rev Rep."},{"key":"B2","article-title":"Coronavirus disease (COVID-19) pandemic","year":"2020"},{"key":"B3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1093\/jac\/dkh519","article-title":"Anti-inflammatory effects of macrolides-an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?","volume":"55","author":"Amsden","year":"2005","journal-title":"J Antimicrobial Chemother."},{"key":"B4","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00228-011-1161-x","article-title":"Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases","volume":"68","author":"Zarogoulidis","year":"2012","journal-title":"Eur J Clin Pharmacol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1128\/CMR.00078-09","article-title":"Mechanisms of action and clinical application of macrolides as immunomodulatory medications","volume":"23","author":"Kanoh","year":"2010","journal-title":"Clin Microbiol Rev."},{"key":"B6","doi-asserted-by":"publisher","first-page":"106053","DOI":"10.1016\/j.ijantimicag.2020.106053","article-title":"Macrolides and viral infections: focus on azithromycin in COVID-19 pathology","volume":"56","author":"Pani","year":"2020","journal-title":"Int J Antimicrobial Agents"},{"key":"B7","doi-asserted-by":"publisher","first-page":"649570","DOI":"10.1155\/2012\/649570","article-title":"Macrolide therapy in respiratory viral infections","volume":"2012","author":"Min","year":"2012","journal-title":"Med Inflam."},{"key":"B8","first-page":"505","article-title":"Pharmacocin\u00e9tique clinique de l'azithromycine","volume":"43","author":"Singlas","year":"1995","journal-title":"Pathol Biol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1128\/AAC.02011-12","article-title":"Blood, tissue, and intracellular concentrations of azithromycin during and after end of therapy","volume":"57","author":"Matzneller","year":"2013","journal-title":"Antimicrobial Agents Chemother."},{"key":"B10","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1093\/ckj\/sfu098","article-title":"Clinical manifestation of macrolide antibiotic toxicity in CKD and dialysis patients","volume":"7","author":"Ma","year":"2014","journal-title":"Clin Kidney J."},{"key":"B11","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1093\/jac\/25.suppl_A.73","article-title":"The pharmacokinetics of azithromycin in human serum and tissues","volume":"25","author":"Foulds","year":"1990","journal-title":"J Antimicrobial Chemother"},{"key":"B12","doi-asserted-by":"publisher","first-page":"370","DOI":"10.2165\/00003088-199325050-00003","article-title":"Azithromycin clinical pharmacokinetics","volume":"25","author":"Lalak","year":"1993","journal-title":"Clin Pharmacokinet."},{"key":"B13","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/BF01975832","article-title":"The pharmacokinetics of azithromycin and their clinical significance","volume":"10","author":"Lode","year":"1991","journal-title":"Eur J Clin Microbiol Infect Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.intimp.2016.09.012","article-title":"Azithromycin modulates immune response of human monocyte-derived dendritic cells and CD4+ T cells","volume":"40","author":"Lin","year":"2016","journal-title":"Int Immunopharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"L1115","DOI":"10.1152\/ajplung.2001.280.6.L1115","article-title":"Bafilomycin A1 inhibits rhinovirus infection in human airway epithelium: effects on endosome and ICAM-1","volume":"280","author":"Suzuki","year":"2001","journal-title":"Am J Physiol Lung Cell Mol Physiol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1164\/ajrccm.165.8.2103094","article-title":"Erythromycin inhibits rhinovirus infection in cultured human tracheal epithelial cells","volume":"165","author":"Suzuki","year":"2002","journal-title":"Am J Respir Crit Care Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1183\/09031936.06.00008005","article-title":"Effect of clarithromycin on rhinovirus-16 infection in A549 cells","volume":"27","author":"Jang","year":"2006","journal-title":"Eur Respiratory J."},{"key":"B18","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1124\/jpet.109.162149","article-title":"Clarithromycin inhibits type a seasonal influenza virus infection in human airway epithelial cells","volume":"333","author":"Yamaya","year":"2010","journal-title":"J Pharmacol Exp Therapeutics."},{"key":"B19","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1093\/jac\/dkn007","article-title":"Azithromycin alters macrophage phenotype","volume":"61","author":"Murphy","year":"2008","journal-title":"J Antimicrobial Chemother."},{"key":"B20","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S0014-2999(02)02042-3","article-title":"Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects","volume":"450","author":"Culi\u0107","year":"2002","journal-title":"Eur J Pharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"667","DOI":"10.7150\/ijbs.5.667","article-title":"Azithromycin suppresses interleukin-12p40 expression in lipopolysaccharide and interferon-\u03b3 stimulated macrophages","volume":"5","author":"Yamauchi","year":"2009","journal-title":"Int J Biol Sci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1183\/09031936.00095809","article-title":"Azithromycin induces anti-viral responses in bronchial epithelial cells","volume":"36","author":"Gielen","year":"2010","journal-title":"Eur Respiratory J."},{"key":"B23","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.pharmthera.2014.03.003","article-title":"Azithromycin: mechanisms of action and their relevance for clinical applications","volume":"143","author":"Parnham","year":"2014","journal-title":"Pharmacol Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1159\/000358366","article-title":"Macrolides attenuate phorbol ester-induced tumor necrosis factor-\u03b1 and mucin production from human airway epithelial cells","volume":"93","author":"Poachanukoon","year":"2014","journal-title":"Pharmacology."},{"key":"B25","doi-asserted-by":"publisher","first-page":"5623","DOI":"10.1167\/iovs.09-4992","article-title":"Suppressive effects of azithromycin on zymosan-induced production of proinflammatory mediators by human corneal epithelial cells","volume":"51","author":"Li","year":"2010","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B26","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.jcrc.2015.12.010","article-title":"Azithromycin use and outcomes in severe sepsis patients with and without pneumonia","volume":"32","author":"Afshar","year":"2016","journal-title":"J Crit Care."},{"key":"B27","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S0140-6736(17)31281-3","article-title":"Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Gibson","year":"2017","journal-title":"Lancet."},{"key":"B28","doi-asserted-by":"publisher","first-page":"302","DOI":"10.3389\/fimmu.2018.00302","article-title":"The immunomodulatory effects of macrolides - a systematic review of the underlying mechanisms","volume":"9","author":"Zimmermann","year":"2018","journal-title":"Front Immunol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"3311","DOI":"10.1002\/art.27689","article-title":"Interleukin-20 antibody is a potential therapeutic agent for experimental arthritis","volume":"62","author":"Hsu","year":"2010","journal-title":"Arthritis Rheumatism."},{"key":"B30","doi-asserted-by":"publisher","first-page":"105949","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","volume":"56","author":"Gautret","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"B31","doi-asserted-by":"publisher","first-page":"30085","DOI":"10.1016\/j.medmal.2020.03.006","article-title":"No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection","volume":"50","author":"Molina","year":"2020","journal-title":"Med Mal Infect."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1001\/jama.2020.8630","article-title":"Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state","volume":"323","author":"Rosenberg","year":"2020","journal-title":"JAMA."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31180-6","article-title":"RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis [published online ahead of print, 2020 May 22] [retracted in: Lancet. 2020 Jun 5;:null]","author":"Mehra","year":"2020","journal-title":"Lancet"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-70143-6","article-title":"In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication","author":"Touret","year":"2020"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.14.988345","article-title":"SARS-CoV-2 invades host cells via a novel route: CD147-spike protein","author":"Wang","year":"2020","journal-title":"BioRxiv"},{"key":"B36","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1097\/INF.0000000000001708","article-title":"Variations in antibiotic and azithromycin prescribing for children by geography and specialty\u2014United States, 2013","volume":"37","author":"Fleming-Dutra","year":"2018","journal-title":"Pediatr Infect Dis J."},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.20944\/preprints202003.0302.v1","article-title":"Focusing on the unfolded protein response and autophagy related pathways to reposition common approved drugs against COVID-19","author":"Nabirotchkin","year":"2020"},{"key":"B38","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.bbrc.2004.08.085","article-title":"In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine","volume":"323","author":"Keyaerts","year":"2004","journal-title":"Biochem Biophys Res Commun."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.2174\/1381612043383791","article-title":"Chloroquine and hydroxychloroquine as inhibitors of human immunodeficiency virus (HIV-1) activity","volume":"10","author":"Romanelli","year":"2004","journal-title":"Curr Pharm Des."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1743-422X-2-69","article-title":"Chloroquine is a potent inhibitor of SARS coronavirus infection and spread","volume":"2","author":"Vincent","year":"2005","journal-title":"VirolJ."},{"key":"B41","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1743-422X-3-39","article-title":"In vitro inhibition of human influenza A virus replication by chloroquine","volume":"3","author":"Ooi","year":"2006","journal-title":"Virol J."},{"key":"B42","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ebiom.2017.09.034","article-title":"Chloroquine, a FDA-approved drug, prevents Zika virus infection and its associated congenital microcephaly in mice","volume":"24","author":"Li","year":"2017","journal-title":"EBioMedicine"},{"key":"B43","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res"},{"key":"B44","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/agm2.12104","article-title":"Pharmaceutical care of chloroquine phosphate in elderly patients with coronavirus pneumonia (COVID-19)","volume":"3","author":"Sun","year":"2020","journal-title":"Aging Medicine."},{"key":"B45","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1186\/s13063-020-04478-w","article-title":"Efficacy of Chloroquine and Lopinavir\/Ritonavir in mild\/general COVID-2019: a prospective, open-label, multicenter randomized controlled clinical study","volume":"21","author":"Xia","year":"2020","journal-title":"Trials"},{"key":"B46","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1021\/jm0601856","article-title":"Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities","volume":"49","author":"Biot","year":"2006","journal-title":"J Med Chem."},{"key":"B47","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/S0049-0172(10)80012-5","article-title":"Mechanism of action of hydroxychloroquine as an antirheumatic drug","volume":"23","author":"Fox","year":"1993","journal-title":"Semin Arthritis Rheum"},{"key":"B48","volume-title":"Physiologically Based Pharmacokinetic Analyses\u2014Format and Content Guidance for Industry","author":"Food","year":"2018"},{"key":"B49","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/psp4.12260","article-title":"Predictive performance of physiologically based pharmacokinetic models for the effect of food on oral drug absorption: current status","volume":"7","author":"Li","year":"2018","journal-title":"CPT."},{"key":"B50","doi-asserted-by":"publisher","first-page":"2000172","DOI":"10.1002\/adtp.202000172","article-title":"Repurposed drugs, molecular vaccines, immune-modulators, and nanotherapeutics to treat and prevent COVID-19 associated with SARS-CoV-2, a deadly nanovector","volume":"4","author":"Dube","year":"2021","journal-title":"Adv Therap."},{"key":"B51","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3390\/pathogens9060501","article-title":"Emerging prevention and treatment strategies to control COVID-19","volume":"9","author":"Singh","year":"2020","journal-title":"Pathogens."},{"key":"B52","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/s41565-020-0737-y","article-title":"COVID-19 vaccine development and a potential nanomaterial path forward","volume":"15","author":"Shin","year":"2020","journal-title":"Nat Nanotechnol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"191","DOI":"10.5483\/BMBRep.2020.53.4.080","article-title":"COVID-19: an update on diagnostic and therapeutic approaches","volume":"53","author":"Iyer","year":"2020","journal-title":"BMB Rep."},{"key":"B54","doi-asserted-by":"publisher","first-page":"E450","DOI":"10.1503\/cmaj.200528","article-title":"Safety considerations with chloroquine, hydroxychloroquine azithromycin in the management of SARS-CoV-2 infection","volume":"192","author":"Juurlink","year":"2020","journal-title":"CMAJ."},{"key":"B55","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1371\/journal.pctr.0020006","article-title":"Randomized dose-ranging controlled trial of AQ-13, a candidate antimalarial, and chloroquine in healthy volunteers","volume":"2","author":"Mzayek","year":"2007","journal-title":"PLoS Clin Trials."},{"key":"B56","doi-asserted-by":"publisher","first-page":"3354","DOI":"10.1128\/AAC.02794-13","article-title":"Pharmacokinetic interactions between primaquine and chloroquine","volume":"58","author":"Pukrittayakamee","year":"2014","journal-title":"Antimicrobial Agents Chemother."},{"key":"B57","doi-asserted-by":"publisher","first-page":"e01846","DOI":"10.1128\/AAC.01846-19","article-title":"High-dose chloroquine for uncomplicated plasmodium falciparum malaria is well tolerated and causes similar QT interval prolongation as standard-dose chloroquine in children","volume":"64","author":"Ursing","year":"2020","journal-title":"Antimicrob Agents Chemother."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1503\/cmaj.140572","article-title":"The cardiovascular safety of azithromycin","volume":"186","author":"Juurlink","year":"2014","journal-title":"CMAJ."},{"key":"B59","doi-asserted-by":"publisher","first-page":"929","DOI":"10.4269\/ajtmh.2007.77.929","article-title":"Azithromycin\/chloroquine combination does not increase cardiac instability despite an increase in monophasic action potential duration in the anesthetized guinea pig","volume":"77","author":"Fossa","year":"2007","journal-title":"Am J Trop Med Hyg."},{"key":"B60","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1186\/1475-2875-13-458","article-title":"Efficacy and safety of a combination of azithromycin and chloroquine for the treatment of uncomplicated Plasmodium falciparum malaria in two multi-country randomised clinical trials in African adults","volume":"13","author":"Sagara","year":"2014","journal-title":"Malar J."},{"key":"B61","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1056\/NEJMoa1811400","article-title":"Effect of adding azithromycin to seasonal malaria chemoprevention","volume":"380","author":"Chandramohan","year":"2019","journal-title":"N Engl J Med."},{"key":"B62","doi-asserted-by":"publisher","first-page":"E46","DOI":"10.1148\/radiol.2020200823","article-title":"Performance of radiologists in differentiating COVID-19 from non-COVID-19 viral pneumonia at chest CT","volume":"296","author":"Bai","year":"2020","journal-title":"Radiology."},{"key":"B63","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.cmi.2020.04.024","article-title":"COVID-19: don't neglect antimicrobial stewardship principles!","volume":"26","author":"Huttner","year":"2020","journal-title":"Clin Microbiol Infect."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1002\/jmv.25945","article-title":"A novel plan to deal with SARS-CoV-2 and COVID-19 disease","volume":"92","author":"Stricker","year":"2020","journal-title":"J Med Virol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep28698","article-title":"Azithromycin induces anti-viral effects in cultured bronchial epithelial cells from COPD patients","volume":"6","author":"Menzel","year":"2016","journal-title":"Sci Rep."},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.29.008631","article-title":"Azithromycin ciprofloxacin have a chloroquine-like effect on respiratory epithelial cells","author":"Poschet","year":"2020","journal-title":"BioRxiv."},{"key":"B67","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.ijantimicag.2018.12.009","article-title":"Spiramycin and azithromycin, safe for administration to children, exert antiviral activity against enterovirus A71 in vitro and in vivo","volume":"53","author":"Zeng","year":"2019","journal-title":"Int J Antimicrob Agents."},{"key":"B68","doi-asserted-by":"publisher","first-page":"104591","DOI":"10.1016\/j.antiviral.2019.104591","article-title":"Efficacy of clarithromycin against H5N1 and H7N9 avian influenza a virus infection in cynomolgus monkeys","volume":"171","author":"Arikata","year":"2019","journal-title":"Antiviral Res."},{"key":"B69","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.antiviral.2014.07.014","article-title":"Nitazoxanide: a first-in-class broad-spectrum antiviral agent","volume":"110","author":"Rossignol","year":"2014","journal-title":"Antiviral Res."},{"key":"B70","doi-asserted-by":"publisher","first-page":"e40","DOI":"10.22037\/aaem.v8i1.645","article-title":"Metronidazole; a potential novel addition to the COVID-19 treatment regimen","volume":"8","author":"Gharebaghi","year":"2020","journal-title":"Arch Acad Emerg Med."},{"key":"B71","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s00705-013-1880-7","article-title":"Inhibitory effect of doxycycline against dengue virus replication in vitro","volume":"159","author":"Rothan","year":"2014","journal-title":"Arch Virol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"fnv195","DOI":"10.1093\/femsle\/fnv195","article-title":"Antiviral activity of doxycycline against vesicular stomatitis virus in vitro","volume":"362","author":"Wu","year":"2015","journal-title":"FEMS Microbiol Lett."},{"key":"B73","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/phar.2395","article-title":"Therapeutic potential for tetracyclines in the treatment of COVID-19","volume":"40","author":"Sodhi","year":"2020","journal-title":"Pharmacotherapy."},{"key":"B74","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1001\/jama.2017.9938","article-title":"Effect of azithromycin on airflow decline\u2013free survival after allogeneic hematopoietic stem cell transplant: the allozithro randomized clinical trial","volume":"318","author":"Bergeron","year":"2017","journal-title":"JAMA."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.642313\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T08:16:41Z","timestamp":1618388201000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.642313\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,14]]},"references-count":74,"alternative-id":["10.3389\/fmed.2021.642313"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.642313","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,14]]},"article-number":"642313"}}